Instrument Inactif

Communiqués Theravance Inc Nasdaq

Actions

US88338T1043

Produits pharmaceutiques

Cours en clôture Nasdaq
- ^USD	-

05/08	Flash résultats (INVA) : Innoviva, Inc. publie un chiffre d'affaires de 119,6 millions de dollars au deuxième trimestre, contre un consensus FactSet de 111,0 millions de dollars	MT
05/08	Innoviva, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

12/08	Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO(R), ZEVTERA(R) and NUZOLVENCE(R) Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award	AQ
11/08	Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award	BU
05/08	Innoviva: Q2 Earnings Snapshot	AQ
05/08	Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress	BU
22/06	Nortiva Bio Launches to Develop Long-Acting Oral Medicines	AQ
18/06	Nortiva Bio Launches to Develop Long-Acting Oral Medicines	BU
16/06	Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets	BU
01/06	Innoviva to Participate in Upcoming Investor Conferences	BU
06/05	Innoviva: Q1 Earnings Snapshot	AQ
06/05	Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress	BU
25/02	Innoviva: Q4 Earnings Snapshot	AQ
25/02	Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress	BU
19/02	Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference	BU
15/12	U.S. FDA Approves NUZOLVENCE(R) (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents	AQ
12/12	U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents	BU
12/12	Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea	BU
25/11	Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference	BU
05/11	Innoviva: Q3 Earnings Snapshot	AQ
05/11	Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress	BU
21/10/25	Antheia Appoints Eric d'Esparbes as Chief Financial Officer	PR
20/10/25	Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025	BU
07/10/25	Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025	BU
26/08/25	Innoviva to Participate in Upcoming Investor Conferences	BU
13/08/25	Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award	BU
06/08/25	Innoviva: Q2 Earnings Snapshot	AQ